Servicio de Análisis Clínicos, Hospital General de Tomelloso, 13700 Tomelloso, Spain.
Bioquímica Clínica, Hospital Vall d'Hebron, 08023 Barcelona, Spain.
Molecules. 2021 Feb 19;26(4):1085. doi: 10.3390/molecules26041085.
Dimethyl fumarate is a cytoprotective and immunomodulatory drug used in the treatment of multiple sclerosis. We performed a bibliometric study examining the characteristics and trends of the top 100 cited articles that include dimethyl fumarate in the title. On 21 September 2020 we carried out an electronic search in the Web of Science (WOS), seeking articles that include the following terms within the title: dimethyl fumarate, BG-12, or Tecfidera. To focus our investigation on original research, we refined the search to include only articles, early access, others, case report, and clinical trials. We obtained a total of 1115 items, which were cited 7169 times, had a citation density of 6.43 citations/item, and an h-index of 40. Around 2010, there was a jump in the number of published articles per year, rising from 5 articles/year up to 12 articles/year. We sorted all the items by the number of citations and selected the top 100 most cited (T100). The T100 had 4164 citations, with a density of 37 citations/year and contained 16 classic research articles. They were published between 1961 and 2018; the years 2010-2018 amassed nearly 80% of the T100. We noted 17 research areas with articles in the T100. Of these, the number one ranking went to neurosciences/neurology with 39 articles, and chemistry ranked second on the T100 list with 14 items. We noticed that the percentage of articles belonging to different journals changed depending on the time period. Chemistry held the highest number of papers during 1961-2000, while pharmacology andneurosciences/neurology led the 2001-2018 interval. A total of 478 authors from 145 institutions and 25 countries were included in the T100 ranking. The paper by Gold R et al. was the most successful with 14 articles, 1.823 citations and a density of 140.23 citations/year. The biotechnological company Biogen led the T100 list with 20 articles. With 59 published articles, the USA was the leading country in publications. We concluded that this study analyzed the use of and research on dimethyl fumarate from a different perspective, which will allow the readership (expert or not) to understand the relevance of classic and recent literature on this topic.
富马酸二甲酯是一种细胞保护剂和免疫调节剂,用于治疗多发性硬化症。我们进行了一项文献计量学研究,研究了标题中包含富马酸二甲酯的前 100 篇被引最多的文章的特征和趋势。2020 年 9 月 21 日,我们在 Web of Science(WOS)中进行了电子搜索,搜索标题中包含以下术语的文章:富马酸二甲酯、BG-12 或 Tecfidera。为了将我们的研究重点放在原始研究上,我们将搜索范围缩小到仅包括文章、预印本、其他、案例报告和临床试验。我们共获得了 1115 项,被引用了 7169 次,引用密度为 6.43 次/项,h 指数为 40。大约在 2010 年,每年发表的文章数量出现了跳跃式增长,从每年 5 篇增加到每年 12 篇。我们按引用次数对所有项目进行了排序,并选择了前 100 名(T100)。T100 有 4164 次引用,引用密度为 37 次/年,包含 16 篇经典研究文章。它们发表于 1961 年至 2018 年之间;2010-2018 年积累了 T100 的近 80%。我们注意到 T100 中有 17 个研究领域的文章。其中,神经科学/神经病学排名第一,有 39 篇文章,化学排名第二,有 14 篇文章。我们注意到,不同期刊的文章比例因时间而有所变化。化学在 1961-2000 年期间拥有最多的论文,而药理学和神经科学/神经病学则在 2001-2018 年期间领先。T100 排名中共有来自 145 个机构和 25 个国家的 478 位作者。Gold 等人的论文是最成功的,有 14 篇文章,1.823 次引用,引用密度为 140.23 次/年。生物技术公司 Biogen 以 20 篇文章位居 T100 榜首。美国以 59 篇发表文章位居榜首。我们的结论是,这项研究从不同的角度分析了富马酸二甲酯的使用和研究,这将使读者(专家或非专家)了解该主题的经典和最新文献的相关性。